|Dr. Horst G. Zerbe Ph.D.||Founder, Chairman, CEO, Pres and Chairman of Scientific Advisory Board||285.75k||N/A||70|
|Mr. Andre Godin CPA, CA||Chief Financial Officer and Exec. VP||247.14k||N/A||53|
|Mr. John Durham B.Sc.||VP of Operations||180.21k||N/A||62|
|Dr. Dana Matzen PH.D.||VP of Bus. and Corp. Devel.||94.99k||N/A||39|
|Ms. Nadine Paiement M.Sc.||Vice-Chair of Scientific Advisory Board and VP of R&D||118.84k||N/A||40|
IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The companys products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimers disease. It is also developing various products, including INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015, and INT0044/2016 based on three delivery platform technologies, which consist of VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology; and AdVersa, a mucoadhesive tablet technology. The company has co-development and commercialization agreements with RedHill Biopharma Ltd.; Par Pharmaceutical Companies, Inc.; and Endo Ventures Ltd., as well as a licensing, development, and supply agreement with Chemo Group. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Saint-Laurent, Canada.
IntelGenx Technologies Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.